This dataset encompass Dare-Eskd-2 trial information, a prospective, randomized, open-label, blinded endpoint trial performed at 3 dialysis clinics between January 2023 and September 2024, that enrolled 80 consecutive adults on chronic dialysis to either once daily dapagliflozin 10mg or standard care for 24 weeks. Efficacy endpoints comprised the change from baseline to 24 weeks in NT-proBNP, KCCQ-CCS, 6-minute walk test distance.